Table 1. Clinical characteristics and sera of patients with COVID-19 (n = 58).
| Characteristics | Total (n = 58) | Mild (n = 50) | Severe (n = 8) | p-Valuea |
|---|---|---|---|---|
| Age: Median (IQR) | 52 (36–61) | 49 (35–58) | 68 (57–77) | <0.01 |
| Age groups: n (%) | ||||
| ≤18 | 2 (2.8) | 2 (4.0) | 0 (0) | |
| 19–40 | 20 (27.8) | 16 (32.0) | 0 (0) | |
| 41–65 | 34 (47.2) | 23 (46.0) | 4 (50.0) | |
| ≥66 | 16 (22.2) | 9 (18.0) | 4 (50.0) | |
| Gender: n (%) | ||||
| Female | 32 (55) | 27 (54.0) | 5 (62.5) | 0.72 |
| Male | 26 (45) | 23 (46.0) | 3 (37.5) | |
| Sera: n (%) |
Total (n = 155) |
Mild (n = 121) |
Severe (n = 34) |
|
| Less than 4 days after symptom onset | 41 (26.5) | 34 (28.1) | 7 (20.6) | 0.39 |
| 4–7 days after symptom onset | 31 (20.0) | 25 (20.7) | 6 (17.6) | |
| 8–14 days after symptom onset | 48 (31.0) | 39 (32.2) | 9 (26.5) | |
| 15–21 days after symptom onset | 23 (14.8) | 15 (12.4) | 8 (23.5) | |
| More than 21 days after symptom onset | 12 (7.7) | 8 (6.6) | 4 (1.8) | |
Abbreviations: IQR, interquartile range.
ap-values indicate differences between mild and severe patients. p < 0.05 is considered statistically significant.